Table 1.
Coronavirus disease 2019 kidney transplant recipients characteristics (n = 321)
|
Characteristics
|
Number (%) of patients
|
Range
|
| Sex | ||
| Male/female | 183/138 (57/43) | |
| Age (yr) [Median (IQR)] Primary kidney disease |
55 (44-64) | 22-81 |
| Glomerulonephritis | 9 + 8 (30.6) | |
| Diabetic nephropathy | 12 (3.8) | |
| ADPKD | 48 (15) | |
| Pyelonephritis | 26 (8.1) | |
| Nephroangiosclerosis | 26 (8.1) | |
| Other | 110 (34.4) | |
| Time from transplantation (months) [Median (IQR)] | 94.5 (52-135.8) | 1-368 |
| Height (cm) [Median (IQR)] | 171 (163-180) | 124-199 |
| Body weight (kg) [Median (IQR)] | 79 (67-92) | 42-150 |
| BMI [Median (IQR)] | 26.5 (23.9-29.2) | 17.36-45.79 |
| Nutritional status | ||
| Underweight (BMI < 18.5) | 4 (1.3) | |
| Normal weight | 105 (32.8) | |
| Pre-obesity (25-29.9) | 144 (45) | |
| Obese (≥ 30) | 67 (20.9) | |
| Previous thrombosis | 30 (9.4) | |
| Previous myocardial infarction or stroke | 32 (10) | |
| Previous CMV infection | 36 (11.3) | |
| Previous BK infection | 68 (21.3) | |
| Previous EBV infection | 28 (8.8) | |
| Allograft rejection | 46 (14.4) | |
| Creatinine value [Median (IQR)] | 129 (98-165.8) | 45-430 |
| CKD EPI [Median (IQR)] | 49 (35-64) | 0.23-133 |
| Biuret [Median (IQR)] | 0.2 (0.1-0.5) | 0-79 |
| Vaccinated against COVID-19 | 246 (76.9) | |
| Before COVID-19 infection | 149 (46.6) | |
| After COVID-19 infection | 97 (30.3) | |
| Number of vaccine doses [Median (IQR)] | 2 (2-3) | 1-4 |
| Number of vaccine doses (n = 246) | ||
| One | 21 (8.5) | |
| Two | 138 (56.1) | |
| Three | 83 (33.7) | |
| Four | 4 (1.6) | |
| COVID-19 initial symptoms | ||
| Febrility | 245 (76.6) | |
| Diarrhea | 39 (12.2) | |
| Respiratory | 230 (71.9) | |
| Asymptomatic | 21 (6.6) | |
| COVID-19 initial complications | ||
| Hospitalisation | 125 (39.1) | |
| Pneumonia | 141 (44.1) | |
| Mechanical ventilation | 4 (1.3) | |
| Other | 66 (20.6) | |
| Initial immunosuppression | ||
| Tacrolimus | 222 (69.4) | |
| Cyclosporin A | 70 (21.9) | |
| Mycophenolate | 280 (87.5) | |
| Azathioprine | 12 (3.8) | |
| Everolimus | 48 (15) | |
| Prednisolone (dose) [Median (IQR)] | 5 (5-5) | 0-30 |
| Acute COVID-19 treatment | ||
| Cessation of MMF/Aza | 133 (41.6) | |
| Decreasing MMF/Aza | 102 (31.9) | |
| Cessation of Tac/CyA | 1 (0.3) | |
| Decreasing Tac/CyA | 29 (9.1) | |
| Hyperimmune anti-CMV globulin | 30 (9.4) | |
| Intravenous immunoglobulin | 13 (4.4) |
COVID-19: Coronavirus disease 2019; ADPKD: Autosomal dominant polycystic kidney disease; CMV: Cytomegalovirus; EBV: Epstein-Barr virus; BKV: BK virus; MMF: Mycophenolate mofetil; Aza: Azathioprine; CyA: Cyclosporine; Tac: Tacrolimus; BMI: Body mass index.